Drug Profile
Lenvatinib - Eisai Co Ltd/Merck & Co
Alternative Names: E 7080; ER-203492-00; Kisplyx; KYSPLIX; Lenvatinib mesylate; LENVIMA; Lenvima; MK 7902Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Developer Curie Institute; Eisai Co Ltd; EMD Serono; Massachusetts Eye and Ear; Merck & Co; Merck Sharp & Dohme; MSD KK; National University Hospital (Singapore); Ono Pharmaceutical; SFJ Pharmaceuticals
- Class Amides; Antineoplastics; Chlorobenzenes; Cyclopropanes; Eye disorder therapies; Phenyl ethers; Quinolines; Small molecules; Urea compounds
- Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Endometrial cancer; Liver cancer; Renal cell carcinoma; Thyroid cancer
- Registered Malignant thymoma
- Phase III Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Urogenital cancer
- Phase II Biliary cancer; Glioblastoma; Kaposi's sarcoma; Malignant-mesothelioma; Neuroendocrine tumours; Osteosarcoma; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Uveal melanoma
- Phase I/II Breast cancer
- Phase I CNS cancer
- No development reported Ovarian cancer
- Discontinued Cancer; Glioma; Lymphoma
Most Recent Events
- 15 Mar 2024 Merck Sharp & Dohme completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Poland, Spain, South Korea, Israel, Germany, China, Canada, USA (PO) (NCT02720068)
- 18 Jan 2024 Efficacy and adverse events data from a phase II trial in Liver cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCo-GCS-2024)
- 18 Jan 2024 Efficacy and adverse events data from a phase III trial in Hepatocellular carcinoma presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)